Systemic Aspergillosis Clinical Trial
Official title:
Safety, Feasibility and Efficacy of Caspofungin Versus Liposomal Amphotericin B as Antifungal Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients - a Retrospective Phase I/II Study
| Verified date | December 2009 |
| Source | University Children’s Hospital Tuebingen |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Germany: Ethics Commission |
| Study type | Observational |
Pediatric patients are at high risk to acquire mycotic infections following allogeneic bone marrow transplantation. In the present retrospective analysis we assess the safety and efficacy of different regimens in antimycotic prophylaxis.
| Status | Completed |
| Enrollment | 0 |
| Est. completion date | December 2009 |
| Est. primary completion date | December 2009 |
| Accepts healthy volunteers | |
| Gender | Both |
| Age group | N/A to 18 Years |
| Eligibility |
Inclusion Criteria: - Pediatric patients under the age of 18 years - Pediatric patients after HSCT treated with caspofungin - Pediatric patients after HSCT treated with liposomal amphotericin Exclusion Criteria: - Pediatric patients with uncontrolled hematological malignancies - Pediatric patients with IFI at start of HSCT |
Observational Model: Cohort, Time Perspective: Retrospective
| Country | Name | City | State |
|---|---|---|---|
| Germany | University Children's Hospital | Tuebingen |
| Lead Sponsor | Collaborator |
|---|---|
| University Children’s Hospital Tuebingen |
Germany,